- Home
- DMAC vs TEI Comparison
DMAC vs TEI Comparison
Compare DMAC & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- TEI
- Stock Information
- Founded
- DMAC 2000
- TEI 1993
- Country
- DMAC United States
- TEI United States
- Employees
- DMAC N/A
- TEI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- TEI Finance Companies
- Sector
- DMAC Health Care
- TEI Finance
- Exchange
- DMAC Nasdaq
- TEI Nasdaq
- Market Cap
- DMAC 321.5M
- TEI 282.9M
- IPO Year
- DMAC N/A
- TEI N/A
- Fundamental
- Price
- DMAC $5.95
- TEI $6.39
- Analyst Decision
- DMAC Strong Buy
- TEI
- Analyst Count
- DMAC 4
- TEI 0
- Target Price
- DMAC $15.50
- TEI N/A
- AVG Volume (30 Days)
- DMAC 315.3K
- TEI 142.4K
- Earning Date
- DMAC 11-12-2025
- TEI 01-01-0001
- Dividend Yield
- DMAC N/A
- TEI 10.51%
- EPS Growth
- DMAC N/A
- TEI N/A
- EPS
- DMAC N/A
- TEI N/A
- Revenue
- DMAC N/A
- TEI N/A
- Revenue This Year
- DMAC N/A
- TEI N/A
- Revenue Next Year
- DMAC N/A
- TEI N/A
- P/E Ratio
- DMAC N/A
- TEI N/A
- Revenue Growth
- DMAC N/A
- TEI N/A
- 52 Week Low
- DMAC $3.19
- TEI $4.35
- 52 Week High
- DMAC $7.49
- TEI $5.39
- Technical
- Relative Strength Index (RSI)
- DMAC 42.03
- TEI 54.05
- Support Level
- DMAC $5.26
- TEI $6.39
- Resistance Level
- DMAC $6.47
- TEI $6.50
- Average True Range (ATR)
- DMAC 0.41
- TEI 0.07
- MACD
- DMAC -0.10
- TEI -0.00
- Stochastic Oscillator
- DMAC 36.50
- TEI 50.00
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.